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Purpose: To describe pharmacological treatment patterns in Asian patients with major depressive 
disorder (MDD), including duration of treatment, reasons for medication discontinuation, rate 
of medication nonadherence, factors associated with medication nonadherence, and impact of 
medication nonadherence on depression outcomes.
Patients and methods: Data were from a prospective, observational 3-month study of East 
Asian MDD inpatients from 40 sites in six East Asian countries who initiated antidepressant treat-
ment at baseline (n=569). Assessments included the Clinical Global Impression-Severity scale 
(CGI-S), 17-item Hamilton Depression Rating Scale (HAMD-17), painful physical symptoms, 
response and remission, employment status, quality of life (QoL) (EuroQOL Questionnaire-5 
Dimensions [EQ-5D]) and health state using the visual analog scale, adherence by clinician 
opinion, and patient self-report. Cox proportional hazards modeling, Kaplan–Meier survival 
analysis, and regression modeling were employed.
Results: Median time to discontinuation for any reason was 70 days (95% confidence interval: 
47; 95). Reasons for discontinuation were inadequate response in 64.1%, nonadherence in 6.2%, 
and adverse events in 4.1%; 25.6% who discontinued experienced an adequate response to 
treatment. In those patients who had an adequate response, age and country were significantly 
associated with time to medication discontinuation. Patient-reported nonadherence was 57.5% 
and clinician-reported nonadherence was 14.6% (62/426). At 3 months, nonadherent patients 
had significantly higher disease severity (CGI-S, P=0.0001; HAMD-17, P0.0001), lower QoL 
ratings (EQ-5D tariff, P=0.0007; EQ-5D visual analog scale, P=0.0024), and lower response 
and remission rates (both P0.0001) compared with adherent patients. The odds of response 
and remission were greater among adherent patients.
Conclusion: Early discontinuation of antidepressants among Asian MDD patients was high. 
A total of 25.6% who discontinued prematurely were experiencing an adequate response to 
treatment. Nonadherent patients had significantly higher disease severity, lower QoL ratings, 
and lower response and remission rates compared with adherent patients.
Keywords: adherence, Asian, major depressive disorder, treatment
Introduction
The psychiatric condition, major depressive disorder (MDD), is associated with 
psychological, behavioral, and physical symptoms. In many patients, MDD requires 
long-term antidepressant treatment to prevent relapse, making adherence with therapy 
a crucial factor in relapse prevention.1 Clinical guidelines recommend several months 
of antidepressant maintenance treatment for MDD; for example, 6 months of treatment 
are recommended in the National Institute of Clinical Excellence (NICE) depression 
guidelines.2
While clinical guidelines recommend prolonged maintenance treatment, early dis-
continuation of treatment is usually high and adherence with therapy in the real-world 
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setting can be poor. Nonadherence with antidepressant 
therapy in Western countries has been estimated to be 
40%–70%,3–6 and it has been suggested that nonadherence 
in Asian countries may be no better.7,8 A retrospective chart 
review of 367 Japanese patients with MDD, for example, 
revealed that fewer than 50% of patients continued antide-
pressant treatment for 6 months.9 Other studies also report 
medication adherence to be poor among Asian patients with 
MDD, with at least 50% of patients found to be nonadherent 
to antidepressant medication.7,10,11
Understanding the reasons for nonadherence with anti-
depressant therapy in MDD will help clinicians to manage 
this problem. Medication discontinuation may occur due to 
treatment-related factors, such as the completion of a course 
of maintenance treatment, but it may also occur due to a 
lack of efficacy, or adverse events when treatment is poorly 
tolerated.1 Medication nonadherence is also associated with 
a number of patient-related factors including young age, 
being a student or in paid employment, a poor doctor–patient 
relationship, low level of income, and a poor understanding 
of the importance of continuing medication.1,11,12
The analysis of antidepressant treatment patterns in MDD 
increases our understanding of the reasons for nonadher-
ence. Most of the studies of medication adherence in Asia 
conducted to date, however, have been cross-sectional or 
based on the analysis of retrospective claims data, so have 
provided little information that is useful in clinical practice. 
Among Asian patients, information on the level of nonad-
herence and impact of nonadherence on patient outcomes is 
particularly limited.
The overall objective of the present analysis was to 
describe pharmacological treatment patterns in Asian patients 
with MDD. Specific objectives included description of the 
duration of antidepressant treatment, the reasons for medi-
cation discontinuation, estimation of the rate of medication 
nonadherence, exploration of the factors associated with 
medication nonadherence, and investigation of the impact of 
medication nonadherence on the outcomes of depression.
Materials and methods
study design and population
This was a post hoc analysis of data from a prospective, 
observational study designed to assess the frequency of 
somatic symptoms in East Asian patients who received treat-
ment for an acute MDD episode. The study was conducted 
in the psychiatric care setting and enrolled patients from 40 
study sites across six East Asian countries and regions (spe-
cifically mainland China [n=300, 33.0%], Hong Kong [n=89, 
9.8%], Malaysia [n=95, 10.5%], Singapore [n=30, 3.3%], 
South Korea [n=197, 21.7%] and Taiwan [n=198, 21.8]). 
Recruitment occurred from June 14, 2006 to February 15, 
2007, with a follow-up period of 3 months. Previous publica-
tions have reported the baseline characteristics of the patients 
with and without painful physical symptoms (PPS)13 and 
changes in quality of life (QoL), patterns of treatment, and 
severity of disease over the 3 months of follow-up.14
Study entry criteria were as follows: inpatients and 
outpatients; aged 18 years; presenting with a new or first 
episode of MDD (defined according to the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition Text 
Revision [DSM-IV-TR]15 or International Classification of 
Diseases, 10th Revision [ICD-10]16 diagnostic criteria); 
moderately ill or worse (ie, a Clinical Global Impression of 
Severity scale [CGI-S]17 score 4); no symptoms of depres-
sion for 2 months prior to the current episode; and consent 
to participate in the study.
Exclusion criteria were as follows: persistence of the 
current depressive episode for 6 (continuous) months; a 
previous or current diagnosis of schizophrenia, schizophreni-
form disorder, schizoaffective disorder, bipolar disorder, or 
dementia; the presence of chronic, treatment-resistant pain or 
inflammatory pain related to an identified medical condition; 
and current participation in another study (with a treatment 
intervention or an investigational drug).
All patients who satisfied the entry criteria were enrolled 
up to the required sample size. No further selection or strati-
fication was performed.
No restrictions nor recommendations were made regard-
ing treatments prescribed during the study; all treatment deci-
sions were based solely on the clinician’s usual practice when 
providing care for MDD patients. Reporting of adverse events 
was conducted in line with each country’s rules, regulations, 
and legislation. The study was performed in accordance with 
the ethical principles that have their origin in the Declaration 
of Helsinki and that are consistent with the International Con-
ference on Harmonization good clinical practice guidelines. 
Institutional or ethical review board approval was obtained 
from at least one site in each country or region. Prior to study 
enrollment, written, informed consent was obtained from all 
patients (or their legal representative).
Measures
Data collected at the baseline visit included demographic 
and clinical data. The severity of depression was assessed 
at baseline and again at 3 months using two measures: the 
17-item Hamilton Depression Rating Scale (HAMD-17)18 
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and the clinician-rated CGI-S. Consistency of HAMD-17 
ratings between clinicians was ensured by training and assess-
ment (rating of a videotaped patient interview). A maximum 
variation of +3 or -3 from the prespecified HAMD-17 total 
score was considered acceptable, plus 60% agreement with 
the 17 individual items. In case of investigators outside the 
acceptable range, retraining was performed until adequate 
consistency with other raters was achieved.
A mean score of greater than or equal to 2 out of a rating 
of 1 to 5 for the pain-related items of the modified Somatic 
Symptom Inventory (SSI) (which includes muscular sore-
ness, headache, lower back pain, abdominal pain, and joint, 
neck, heart, and chest pain) defined the presence of PPS at 
baseline.19 The SSI is a patient self-report scale that measures 
(on a scale of 1 [“not at all”] to 5 [“a great deal”]) the extent 
to which 28 somatic symptoms bothered the patient during 
the previous week.
Response was defined as a reduction of 50% in HAMD-17 
total score from baseline to endpoint. Remission was defined 
as a HAMD-17 total score of 7 at study endpoint.
Patient perception of QoL and health status was assessed 
using the EuroQOL Questionnaire-5 Dimensions (EQ-5D),20 
which is a self-rated, generic, health-related QoL instrument 
that consists of two parts: 1) five questions on general health 
covering the dimensions of mobility, self-care, usual activi-
ties, pain/discomfort, and anxiety/depression (EQ-5D); and 
2) a visual analog scale (VAS) that patients use to assess 
their current level of health on the day of scoring from 0 
(worst imaginable health state) to 100 (best imaginable health 
state) (EQ-5D VAS). The five questions on general health 
were translated into QoL tariff scores using the available UK 
population tariffs.21
Data describing patterns of treatment (including the spe-
cific antidepressants and other medications prescribed) were 
collected at baseline and during the follow-up period. Antide-
pressants were classified into the following groups: tricyclic 
and tetracyclic antidepressants, selective serotonin reuptake 
inhibitors (SSRIs), serotonin norepinephrine reuptake inhibi-
tors, and other antidepressants (dopamine reuptake inhibitors, 
monoamine oxidase inhibitors, noradrenergic and specific 
serotonergic antidepressants).
Adherence was evaluated at 3 months both by the clini-
cian and by the patient. Clinicians were asked to provide their 
opinion on whether the patient had been adherent with the 
prescribed medication(s) for MDD since the baseline visit; 
Patients taking a daily medication dose between 80% and 
120% of the prescribed medication were considered adher-
ent (as patients may take more medication than prescribed). 
Patients were asked how regularly they took the medications 
prescribed for MDD since the baseline visit, with the options 
of: 1, “I never missed taking my medicine”; 2, “I missed only 
a couple of times but basically took all medicine”; 3, “I missed 
taking the medicine several times but took at least half of it”; 
4, “I took less than half of what was prescribed”; and 5, “I 
stopped taking the medicine altogether”. Only those patients 
answering 1 were considered adherent.
Medication discontinuation refers to the medication no 
longer being prescribed by his/her doctor. The date of medi-
cation discontinuation was defined as the date that the patient 
was no longer prescribed the antidepressant medication. If 
the patient started two or more medications at the baseline 
visit, the medication discontinuation date was taken as the 
first date of medication discontinuation. Reasons for medica-
tion discontinuation were adequate response, adverse event, 
inadequate response, and nonadherence.
statistical analysis
Patients who initiated an antidepressant medication at base-
line and were also evaluated at 3 months were included in 
this analysis. Descriptive statistics were used to characterize 
patients at study entry.
Cox proportional hazards modeling was used to evaluate 
the possible effect of covariables on time to discontinuation. 
Survival analysis with competing risks were used to analyze the 
influence of different reasons for discontinuation. A Kaplan–
Meier product limit estimation method was used to assess the 
time to medication discontinuation. The association between 
adherence and the outcomes of depression were analyzed using 
regression models; multiple linear regression was used for 
continuous variables (HAMD-17 score, CGI-S, EQ-5D score, 
and VAS), and logistic regression was used for categorical 
variables (response and remission). All models were adjusted 
by age, sex, the baseline value of the outcome variable, and 
any other variable associated with the outcome. In the case of 
remission and response, HAMD-17 was included as a covari-
ate. The main analysis was conducted using clinician-reported 
adherence. A sensitivity analysis was conducted using patient-
reported adherence instead of clinician-reported adherence.
All statistical analyses were performed using SAS© ver-
sion 9.2 for Windows™ (SAS Institute Inc., Cary, NC, USA). 
The level of statistical significance was defined a priori as a 
two-sided P-value of 0.05.
Results
A total of 909 patients were enrolled in the study; of these 
patients, 13 patients were not taking antidepressants, and 247, 
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80, and 569 patients started antidepressant treatment before, 
after, and at the baseline visit, respectively. The patients 
included in this analysis were the 569 patients who started 
antidepressant treatment at the baseline visit.
Comparison of the baseline demographics and clinical 
characteristics of the patients who were followed (ie, with 
both baseline and endpoint assessment, n=430, 75.6%) and 
those lost to follow-up (ie, with baseline assessment only, 
n=139, 24.4%) revealed that there were no significant dif-
ferences between the groups in the proportion of women, 
severity of depression (HAMD-17), QoL (EQ-5D tariff and 
VAS score), or comorbidities (Table 1). There were sig-
nificant differences between the groups with regard to PPS+ 
status, employment status, and disease severity; compared 
with patients who were assessed at 3 months, patients lost 
to follow-up were more likely to be PPS+ (P=0.0388), to be 
in full-time employment (P=0.0117), and to have less severe 
disease (CGI-S score) (P=0.0094).
Mean (standard deviation [SD]) age of the 430 patients 
was 46.25 (SD 14.00) years and 67.4% were women. Time 
to medication discontinuation among the 430 patients for 
whom both baseline and 3-month assessments were available 
is shown in Figure 1. The rate of medication discontinuation 
was rapid during the first 10 days, and then slowed thereafter; 
242 (56.3%) patients had discontinued their medication by 
3 months, and 188 (43.7%) continued treatment. The median 
time to discontinuation for any reason was 70 days (95% con-
fidence interval [CI]: 47; 95). Among the 242 patients who 
discontinued treatment, the reasons for discontinuation were 
inadequate response to treatment in 155 (64.1%) patients, 
nonadherence in 15 (6.2%) patients, and adverse events in 
ten (4.1%) patients; 62 (25.6%) patients who discontinued 
experienced an adequate response to treatment. Among the 
patients experiencing an adequate response to treatment, 
mean (SD) time to discontinuation was 48.7 (40.1) days, 
with a median time to discontinuation of 47.5 days. Among 
the patients experiencing an inadequate response, mean 
(SD) time to discontinuation was 20.5 (SD 21.1) days, with 
a median time to discontinuation of 13 days.
Cox regression analysis revealed that, in patients with a 
good response to treatment, age and country were factors that 
were significantly associated with time to discontinuation. 
Older patients discontinued treatment significantly earlier 
than younger patients (hazard ratio [HR] 1.027 [95% confi-
dence limits (CL); 1.008; 1.047], P=0.0049). Patients from 
Hong Kong, Malaysia/Singapore, and Taiwan discontinued 
treatment significantly later than patients from the People’s 
Republic of China; the HR for time to discontinuation was 
0.235 (95% CL: 0.069; 0.794, P=0.0198) for Hong Kong, 
0.344 (95% CL: 0.126; 0.937, P=0.0370) for Malaysia/
Singapore, and 0.356 (95% CL: 0.153; 0.829, P=0.0166) 
for Taiwan. Other variables (ie, sex, presence of PPS+, 
and medication) were not significantly associated with dis-
continuation. In patients with an inadequate response to or 
intolerant of treatment, country was the only factor that was 
significantly associated with time to discontinuation; patients 
Table 1 Baseline patient demographics and clinical characteristics (n=569)
Characteristic Patients with only  
baseline assessment
(n=139)
Patients with baseline  
and endpoint assessments
(n=430)
P-value
Women, n (%) 93 (66.9) 290 (67.4) 0.9069
Married, n (%) 93 (66.9) 301 (70.0) 0.5962
PPs+, n (%) 87 (62.6) 226 (52.6) 0.0388
comorbidities, n (%)
0 109 (79.6) 349 (81.5) 0.7575
1 21 (15.3) 63 (14.7)
1+ 7 (5.1) 16 (3.7)
employment status, n (%)
Full-time 58 (42.6) 140 (32.6) 0.0117
Part-time 11 (8.1) 29 (6.8)
student 7 (5.1) 27 (6.3)
retired 6 (4.4) 65 (15.2)
Unemployed 54 (39.7) 168 (39.2)
cgi-s, mean (sD) 4.60 (0.75) 4.76 (0.72) 0.0094
hAMD-17 total score, mean (sD) 24.24 (5.90) 23.96 (5.55) 0.6021
eQ-5D tariff score, mean (sD) 0.48 (0.36) 0.44 (0.34) 0.1697
eQ-5D VAs score, mean (sD) 47.50 (21.12) 45.80 (19.65) 0.3275
Abbreviations: cgi-s, clinical global impression–severity; eQ-5D, euroQOl Questionnaire-5 Dimensions; hAMD-17, 17-item hamilton Depression rating scale; PPs, 
painful physical symptoms; sD, standard deviation; VAs, visual analog scale.
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from Korea discontinued treatment significantly earlier than 
patients from the People’s Republic of China (HR 1.879 [95% 
CL: 1.256; 2.812], P=0.0022).
Mean daily doses for the antidepressants taken during the 
study are shown in Table 2. SSRIs were the most commonly 
prescribed antidepressants.
Information on adherence during the follow-up period 
was available for 426 patients (in four out of the 430 cases, 
there was no information about adherence). Patient-reported 
nonadherence was 57.5% (245/426), and clinician-reported 
nonadherence was 14.6% (62/426). Based on clinician-
reported adherence data, there were no significant differences 
in the demographics and clinical characteristics between the 
two adherence groups at baseline except for a significant 
difference in EQ-5D tariff scores. Mean (SD) EQ-5D tariff 
scores were 0.37 (SD 0.36) for nonadherent patients and 0.46 
(SD 0.34) for adherent patients (P=0.0364), indicating that 
QoL at baseline was slightly better in the adherent patients. 
The remaining demographic and clinical characteristics 
of the two groups were similar; mean (SD) age was 45.0 
(SD 14.8) and 46.3 (SD 13.8) years; 69.4% and 67.9% of 
patients were women; 66.1% and 70.6% were married; and 
37.1% and 32.2% were in full-time employment in nonad-
herent and adherent patients, respectively. With regard to 
clinical characteristics, 75.8% and 82.9% of patients had 
no comorbidities; 33.3% and 39.8% had experienced a 
previous MDD episode; 59.7% and 51.1% were PPS+; 48.4% 
and 59.1% of patients received SSRIs (the most common 
antidepressant); and 6.5% and 8% received more than one 
antidepressant, in nonadherent and adherent patients, respec-
tively. Mean (SD) CGI-S scores were 4.69 (SD 0.69) and 4.77 
(SD 0.72); HAMD-17 scores were 23.19 (SD 6.36) and 24.07 
(SD 5.43); and EQ-VAS scores were 48.84 (SD 20.10) and 
45.36 (SD 19.62), in nonadherent and adherent patients, 
respectively.
Adherence had a significant effect on outcomes at 
3 months. Compared with adherent patients, nonadherent 
patients had significantly higher disease severity (CGI-S, 
P=0.0001; HAMD-17, P0.0001), significantly poorer 
QoL (EQ-5D tariff, P=0.0007; EQ-5D VAS, P=0.0024), 
and significantly lower response (P0.0001) and remission 
rates (P0.0001) (Table 3).
When adjusted for the presence of other clinical and 
sociodemographic factors using linear regression models, 
the impact of clinician-reported adherence on outcomes at 
3 months was as follows. With regard to depression severity, 
nonadherent patients had an estimated CGI-S total score that 
was 0.64 points (95% CI: 0.38; 0.90) higher, and an estimated 
HAMD-17 score that was 4.54 points (95% CI: 3.12; 5.96) 
higher than that of adherent patients, indicating that disease 
severity was lower among adherent patients. With regard to 
QoL, nonadherent patients had an estimated EQ-5D VAS 
score that was 7.85 points (95% CI: -12.77; -2.94) lower, 
and an estimated EQ-5D tariff score that was 0.13 points 
(95% CI: -0.19; -0.06) lower than that of adherent patients, 
indicating that QoL was higher among adherent patients. 
Response and remission rates also differed significantly 
with adherence; response rates were 50.8% in nonadherent 
patients and 78.6% in adherent patients (P0.0001), and 
remission rates were 31.1% in nonadherent patients and 
60.2% in adherent patients (P0.0001). Compared with 
nonadherent patients (using logistic regression modeling), 
the odds ratio of response among adherent patients was 3.97 
(95% CI: 2.12; 7.45), and the odds ratio of remission was 4.30 
(95% CI: 2.21; 8.38), indicating that the odds of response and 
remission were greater among adherent patients.
Figure 1 Time to antidepressant medication discontinuation (n=430).
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Table 2 Mean daily doses taken by study participants for the 
most commonly used ADs
Group Name Number  
of patients
Dose (mg/day)
Mean (SD) Range
ssris escitalopram 52 9.81 (4.20) 5–20
Fluoxetine 60 20.50 (11.11) 10–80
Paroxetine 67 19.01 (6.68) 10–45
snris Venlafaxine 55 89.13 (49.46) 25–263
Duloxetine 15 38.00 (17.81) 30–90
TcAs Dosulepin 7 42.86 (18.90) 25–75
Trazodone 5 80.00 (67.08) 50–200
Other ADs Mirtazapine 46 25.36 (11.70) 4–60
Bupropion 12 156.25 (59.47) 75–300
Abbreviations: ADs, antidepressants; sD, standard deviation; snris, serotonin 
norepinephrine reuptake inhibitors; ssris, selective serotonin reuptake inhibitors; 
TcAs, tricyclic and tetracyclic antidepressants.
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In the sensitivity analysis of the impact of adherence 
on outcomes at 3 months, findings using patient-reported 
adherence on the severity of depression, QoL, and rates of 
response and remission were consistent with the findings 
from clinician-reported adherence, although the size of the 
differences was smaller.
Discussion
The discontinuation rate among patients starting antidepres-
sant treatment in our study of Asian MDD patients was high 
(56.3%), indicating that more than half of the patients stopped 
taking their antidepressants before 3 months. This finding of 
premature discontinuation of antidepressant therapy is in line 
with estimates of discontinuation of 46%–83% from a wide 
variety of other studies in Asian patient populations. A gen-
eral antidepressant discontinuation rate of 50%, for example, 
was reported for Taiwanese patients,11 while discontinuation 
rates include 46% at 3 months for Japanese patients,9 59% 
at 6 months among Thai patients,7 72% at 6 months among 
Korean patients,22 and 83% at 6 months among Taiwanese 
patients.8 Studies conducted in Westernized populations 
include premature antidepressant discontinuation rates of 
22%–42%.4,5,23,24 It is possible, therefore, that discontinua-
tion rates may be higher in Asian populations. These differ-
ences could be due to differences in cultural beliefs about 
medication, mental illness, and stigma surrounding mental 
disorders.25
One-quarter of patients (25.6%) who discontinued in the 
present study, were, surprisingly experiencing an adequate 
response to treatment. This finding highlights the fact that 
treatment for many Asian MDD patients is not in line with 
clinical guidelines that recommend that MDD treatment 
should be maintained for up to 9 months.2,26 The present 
analysis was not designed to explore reasons for early dis-
continuation, but other studies have suggested that these 
might include patient perceptions about their treatment (eg, 
feeling uninvolved in treatment decisions or disagreeing with 
the diagnosis of MDD), as well as lack of awareness of the 
need to continue therapy and when they should expect to 
feel better,5,27,28 which might explain stopping therapy while 
experiencing an adequate response. In a study of Taiwanese 
MDD patients, lack of insight into MDD was found to predict 
premature treatment discontinuation, and “self-reported recov-
ery” was the most common reason for discontinuation despite 
the fact that more than half of these patients had not reached 
full remission.29 Thus, early discontinuation could be due to 
treatment decisions based on personal criteria from the patient 
and the physician rather than evidence-based criteria.
Among patients with a good response to treatment, age 
and country were significantly associated with time to discon-
tinuation, indicating that, compared with younger patients, 
older patients take their medication for a shorter period of 
time when it is effective, and that patients in specific countries 
take their medication for longer. The finding that older age 
is associated with medication discontinuation in the present 
analysis differs from other studies that have reported that 
older age is associated with lower discontinuation rates,5,8,12,29 
or that this is not a significant factor.1,23 Again, these could 
be due to differences in cultural beliefs from diverse age 
cohorts in participating countries. The present study did not 
find sex to be associated with discontinuation, in line with a 
number of studies,1,23 but also did not find medication to be 
associated with discontinuation, which differs from findings 
from Hansen et al.23
Table 3 Outcomes at 3 months by clinician-reported adherence (n=426)
Outcome Nonadherent  
(n=62)
Adherent  
(n=364)
P-value Adjusted difference 
(95% CI)a
cgi-s, mean (sD) 2.85 (1.28) 2.19 (1.10) 0.0001 0.64 (0.38; 0.90)
hAMD-17 total score, mean (sD) 11.59 (7.31) 6.98 (5.70) 0.0001 4.54 ( 3.12; 5.96)
eQ-5D tariff score, mean (sD) 0.68 (0.32) 0.82 (0.24) 0.0007 -0.13 (-0.19; -0.06)
eQ-5D VAs score, mean (sD) 67.20 (19.93) 74.68 (19.77) 0.0024 -7.85 (-12.77; -2.94)
response, n (%)
no 30 (49.2) 78 (21.4)
Yes 31 (50.8) 286 (78.6) 0.0001 3.97 (2.12; 7.45)
remission, n (%)
no 42 (68.9) 145 (39.8)
Yes 19 (31.1) 219 (60.2) 0.0001 4.30 (2.21; 8.38)
Notes: Percentages may not equal 100 due to rounding. aAdjusted difference using linear regression models for cgi-s, hAMD-17, eQ-5D VAs, and eQ-5D tariff and logistic 
regression models for response and remission. For linear regression models, values correspond to coefficient (95% CI); for logistic regression models, values correspond 
to odds ratio (95% ci).
Abbreviations: 95% CI, 95% confidence interval; CGI-S, Clinical Global Impression–Severity; EQ-5D, EuroQOL Questionnaire-5 Dimensions; HAMD-17, 17-item Hamilton 
Depression rating scale; sD, standard deviation; VAs, visual analog scale.
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Treatment patterns in Asian patients with depression
The most common reason for discontinuation was 
inadequate response to treatment (in 64.1% patients), which is 
much higher than the 2%–22% of patients who discontinued 
due to lack of efficacy in other studies.24,30–32 Adverse events 
were the reason for discontinuation in 4.1% of patients, which 
is much lower than the discontinuation rate due to adverse 
events (8%–36%) reported in some studies,5,24,27,28,32,33 but 
similar to the 5% of patients who discontinued due to adverse 
events in others.30,31 The median time to discontinuation for 
any reason was 70 days (95% CI: 47; 95). The finding that 
the rate of medication discontinuation was rapid initially and 
then slowed thereafter is in line with other studies that have 
also reported the antidepressant discontinuation rate to be 
greatest during the first few weeks of therapy,22,30,32 and may 
imply that interventions trying to increase adherence need to 
occur early during treatment.
In the present analysis, adherence had a significant impact 
on outcomes at 3 months. Compared with adherent patients, 
nonadherent patients had significantly higher disease severity 
(CGI-S and HAMD-17), lower QoL ratings (EQ-5D tariff 
and VAS), and lower response and remission rates. These 
findings were consistent whether adherence was assessed by 
the clinician or by the patient. This is in line with findings 
from other studies.34,35
limitations
A number of limitations should be taken into account when 
considering the findings of this analysis. Given the observa-
tional design of the study, our findings should be interpreted 
conservatively. Patients were recruited from specialized 
mental health services and it is unclear whether our results 
apply to patients in other care settings, such as primary care. 
A follow-up of 3 months is a short time period for an analy-
sis of medication discontinuation. A substantial number of 
patients were taking antidepressant medication at the baseline 
visit, so were not included in the analysis. Due to the observa-
tional nature of the study, we were not able to study the effects 
of early treatment discontinuation. Almost one-fourth of the 
patients were lost to follow-up; these patients had more PPS 
and overall disease severity. Adherence was assessed by the 
clinicians based on limited information, and the use of more 
precise assessment methods could provide more accurate data 
on adherence. Finally, adherence and clinical outcomes were 
assessed by clinicians at the same follow-up visit.
Conclusion
Premature discontinuation of antidepressants among Asian 
MDD patients was high; more than half of the patients 
stopped taking antidepressants before 3 months. Moreover, 
one-quarter of patients (25.6%) with premature discontinu-
ation were experiencing an adequate response to treatment. 
This finding highlights the fact that treatment for many Asian 
MDD patients is not in line with clinical guidelines that 
recommend that MDD treatment should be maintained for 
up to 9 months. Medication nonadherence had a significant 
impact on outcomes; nonadherent patients had significantly 
higher disease severity, lower QoL ratings, and lower 
response and remission rates at 3 months compared with 
adherent patients.
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